Abcam Plc (ABC) Given Consensus Rating of “Hold” by Brokerages
Abcam Plc (LON:ABC) has been given an average rating of “Hold” by the six ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is GBX 1,075.20 ($14.58).
Several analysts have issued reports on the company. Peel Hunt upped their price objective on Abcam from GBX 1,020 ($13.83) to GBX 1,100 ($14.92) and gave the company a “hold” rating in a research note on Monday. JPMorgan Chase & Co. restated a “neutral” rating and issued a GBX 946 ($12.83) price objective on shares of Abcam in a research note on Monday, January 8th. Berenberg Bank restated a “buy” rating and issued a GBX 1,240 ($16.82) price objective on shares of Abcam in a research note on Friday, January 5th. Finally, Numis Securities upgraded Abcam to a “buy” rating and set a GBX 1,200 ($16.27) price objective on the stock in a research note on Friday, January 5th.
Shares of Abcam (LON:ABC) opened at GBX 1,131 ($15.34) on Monday. Abcam has a twelve month low of GBX 9.73 ($0.13) and a twelve month high of GBX 1,156 ($15.68). The stock has a market capitalization of $2,300.00 and a PE ratio of 5,385.71.
Abcam Company Profile
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.